Apremilast for Erythema Multiforme
- Conditions
- Erythema Multiforme
- Registration Number
- NCT05875714
- Lead Sponsor
- Robert Micheletti
- Brief Summary
This study is recruiting patients with chronic, treatment resistant erythema multiforme (EM), which is a disease that can affect the skin and mucous membranes (mucocutaneous). EM often impacts quality of life with pain, anorexia, hospitalization, and related long-term issues. While there are medications used to treat EM, no single therapeutic agent has been consistently effective for long-term management of disease. Apremilast (trade name: Otezla) is approved to treat Bechet's Disease, a different but similar mucocutaneous disease. In this study, eligible patients will receive apremilast for 6 months of treatment so we can evaluate if there is a difference in pain and the number of EM flares compared to prior to treatment with apremilast.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 8
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method EM flares on medication 24 weeks Change in frequency and duration of EM flares at 24-week evaluation.
- Secondary Outcome Measures
Name Time Method Pain on medication 24 weeks Change in pain severity (on 0 to 10 scale) of EM flares at 24-week evaluation
Pain off medication 36 weeks Change in pain severity (on 0-10 visual analogue scale) of EM flares at 36-week follow-up.
Flares off medication 36 weeks Change in frequency and duration of flares at 36-week follow-up.
Prednisone 36 weeks Use of prednisone as rescue therapy to treat flares.
Trial Locations
- Locations (1)
Perelman Center For Advanced Medicine
🇺🇸Philadelphia, Pennsylvania, United States